![BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE)](/upload/1124/V69883.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Opioid Receptor[1]
BW-180C targets the δ-opioid receptor (DOR) as an agonist. It also activates mu-opioid receptors (MOR), and the activation of both mu- and delta-opioid receptors mediates the analgesia brought on by BW-180C. As a member of the enkephalin family, it is an endogenous opioid peptide analog. The compound's dual activity at DOR and MOR makes it a valuable tool for studying opioid receptor signaling and the mechanisms of analgesia. Its neuroprotective properties suggest additional applications in neurodegenerative disease research. |
|---|---|
| ln Vitro |
In SH-SY5Y cells, BW-180C ([D-Ala2, D-Leu5]-Enkephalin) dramatically decreases cellular transcription without endangering the cells. After primary neurons recover for 72 hours in the absence of BW-180C, transcriptional activity fully resumes[1].
In vitro, BW-180C activates both mu- and delta-opioid receptors. As a DOR agonist, it is used to study opioid receptor-mediated signaling pathways. The compound's neuroprotective properties suggest activity in neuronal cell models. Detailed in vitro characterization data, including receptor binding assays and functional signaling studies, are available in the primary literature. The compound's dual receptor activity makes it a valuable tool for studying the interplay between DOR and MOR signaling. |
| ln Vivo |
BW-180C ([D-Ala2, D-Leu5]-Enkephalin) defends against IR damage in hepatocytes but not in rat liver sinusoidal endothelial cells. Although the BW-180C group's GPT levels are much lower than the Control group's, the two groups' serum HA levels are the same. In comparison to the Control group, the BW-180C group's liver tissue MDA concentrations are noticeably lower[2]. The activation of both mu- and delta-opioid receptors mediates the analgesia brought on by BW-180C (DADLE)[3].
In vivo, BW-180C produces analgesia mediated by the activation of both mu- and delta-opioid receptors. As a neuroprotective agent, it may have potential for in vivo investigations of neuroprotection and pain modulation. However, specific in vivo efficacy data and detailed animal model studies for this compound are limited in publicly available sources. Further research is needed to establish its full in vivo activity profile. The compound remains a research tool for opioid receptor pharmacology and neuroprotection studies. |
| Enzyme Assay |
For opioid receptor binding assays, membrane preparations from cells expressing recombinant DOR or MOR are incubated with radiolabeled ligands and varying concentrations of BW-180C. Non-specific binding is determined using excess unlabeled reference compounds (e.g., naloxone for MOR, naltrindole for DOR). Following incubation at appropriate temperature (typically 25°C for 60-90 minutes), bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed and radioactivity counted by liquid scintillation. Ki values are calculated from competition curves. For functional assays, G protein activation is measured by [35S]-GTPγS binding.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Human neuroblastoma cells, SH-SY5Y cells Tested Concentrations: 100 pM to 10 μM Incubation Duration: 24-72 hrs (hours) Experimental Results: Dramatically inhibited cellular transcription. Western Blot Analysis[1] Cell Types: Primary Cortical neurons Tested Concentrations: 100 nM Incubation Duration: 72 hrs (hours) Experimental Results: Treatment Dramatically diminished phosphorylation of RNA polymerase II at both Ser 2 and Ser 5. For in vitro cellular assays, cell lines expressing DOR or MOR (e.g., CHO or HEK293 cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). BW-180C is dissolved in DMSO or appropriate buffer and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Receptor activation is assessed by measuring downstream signaling (e.g., cAMP inhibition, calcium flux, or ERK phosphorylation). Cell viability and neuroprotection can be assessed using standard assays. Each concentration is tested in replicate wells with vehicle controls and positive controls. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats weighing 200 to 250 g[2]
Doses: 5 mg/kg Route of Administration: Administered intravenously (iv) into the inferior vena cava Experimental Results: After 120 min of reperfusion, the serum GPT levels were Dramatically lower in the DADLE group than in the Control group. Animal/Disease Models: Male C57BL/6 mice (age, 35-42 days; weight, 18-22 g; 6 mice in each group)[3] Doses: 5 mg/kg Route of Administration: Injected intraperitoneally (ip) 15 min prior to I/R Experimental Results: The serum levels of AST and ALT in the serum DADLE group were Dramatically lower. For in vivo animal studies of BW-180C, no specific published protocols are available. For general in vivo administration of opioid receptor agonists, compounds are typically formulated in suitable vehicles and administered via intraperitoneal (i.p.) injection, subcutaneous (s.c.) injection, or intracerebroventricular (i.c.v.) injection. Dosing regimens vary by study objective. For pain models, nociceptive responses are measured. For neuroprotection studies, animals may be subjected to ischemic or excitotoxic injury models. All procedures must follow institutional animal care and use committee guidelines. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BW-180C are characteristic of a peptide. The compound has a molecular weight of 555.67, formula C29H39N5O7, and CAS number 63631-40-3. Sequence: H-Tyr-D-Ala-Gly-Phe-D-Leu-OH. Purity: 99.92%. Storage: typically at -20°C for powder; in solvent at -80°C. As a peptide, it is typically administered parenterally and may have limited oral bioavailability and short half-life due to proteolytic degradation. Specific pharmacokinetic parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
According to available safety information, BW-180C is intended for research purposes only and is not for human use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References |
|
| Additional Infomation |
A delta-selective opioid (analgesic, opioid). It can cause a transient decrease in mean arterial blood pressure and heart rate.
BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is a δ-opioid receptor (DOR) agonist and neuroprotective agent. Activation of both mu- and delta-opioid receptors mediates its analgesic effects. It has a molecular weight of 555.67 and formula C29H39N5O7. It is for research use only with no clinical development or regulatory approvals reported. |
| Molecular Formula |
C29H39N5O7
|
|---|---|
| Molecular Weight |
569.65
|
| Exact Mass |
569.285
|
| CAS # |
63631-40-3
|
| PubChem CID |
6917707
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.489
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
41
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
|
| InChi Key |
ZHUJMSMQIPIPTF-IBURTVSXSA-N
|
| InChi Code |
InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1
|
| Chemical Name |
(2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (438.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7555 mL | 8.7773 mL | 17.5546 mL | |
| 5 mM | 0.3511 mL | 1.7555 mL | 3.5109 mL | |
| 10 mM | 0.1755 mL | 0.8777 mL | 1.7555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
